The company has continued to strengthen its position in health-focused beverages through acquisitions, including its recent purchase of Australia-based Made Group. Specialised Nutrition delivered an improved performance supported by a catch-up in the Middle East and a progressive recovery in Europe throughout Q2. North America saw continued strong growth in High Protein with Specialised Nutrition, both Medical Nutrition, driven by Neocate and infant milk formula across Latin America delivering double-digit growth. The APAC region also saw “solid growth” in specialised Nutrition, with EDP in Japan seeing continued strong activation driving demand for Oikos and Activia. Antoine de Saint-Affrique, added: “Demand for our winning platforms remained strong, including High-protein products and Medical Nutrition across all regions, and Skyr, Kefir and Plant-based in Europe.”